KOL | Jan A Walewski |
KOL Resume for Jan A Walewski
| Year |
|---|
Jan A Walewski: Influence Statistics
| Concept | World rank |
|---|---|
| h8 trial | #42 |
| chemotherapy involvedfield radiotherapy | #58 |
| subtotal nodal | #91 |
Open the FULL List in Excel | |
Prominent publications by Jan A Walewski
BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure.
METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared ...
| Known for Involvedfield Radiotherapy | Stage Hodgkin | Chemotherapy Involved | Mechlorethamine Vincristine | Year Survival |
Key People For Involvedfield Radiotherapy
Jan A Walewski:Expert Impact
Concepts for whichJan A Walewskihas direct influence:Involvedfield radiotherapy, Chemotherapy involvedfield radiotherapy, Stage hodgkin, Involved field, Field radiotherapy, Earlystage hodgkins disease, Event free survival, Mechlorethamine vincristine.
Jan A Walewski:KOL impact
Concepts related to the work of other authors for whichfor which Jan A Walewski has influence:Hodgkin lymphoma, Radiation therapy, Early stage, Cycles abvd, Patients hl, Escalated beacopp, Positron emission.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |